HGH Fragment 176-191

Human Growth Hormone Fragment 176-191GH Axis

Evidence grade

DResearch/compounded/adjunct (no established FDA indication)

Cardiovascular · 0–5 · separate axis

Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeGH Axis / Fat metabolism

MechanismThe C-terminal lipolytic domain of human growth hormone, isolated from the rest of the molecule so that fat-metabolism effects are separated from GH growth signalling.

EffectsStudied for lipolysis without the insulin-resistance and glucose-intolerance seen with full-length growth hormone.

DosingNo human dose established.

Bottom lineFrequently confused with AOD-9604, which is the one that was actually trialled — and which failed its Phase IIb endpoint.

Not a dose · what the literature contains instead

Its modified analogue AOD-9604 used 1 mg/day in 12- and 23-week obesity trials; those produced about 2.6–2.8 kg of weight loss against 0.8 kg on placebo, but the Phase IIb trial missed its primary endpoint and development for obesity stopped around 2007.

Batches on filenone

No tested batches on file.

Read with

The library records no pairings for this entry.

Cautions & interactions

No human data on the unmodified fragment. Injection-site reactions reported. Do not read AOD-9604 trial results as evidence for this molecule.

No human interaction data for the unmodified fragment.

CV 2 of 5 — Unlike full-length GH, neither the fragment nor AOD-9604 impaired carbohydrate metabolism in study. No cardiovascular outcomes data.